World Lung 2025 – Candel looks to a new agla-vec use
But results come from a curated dataset, with no in-trial comparator.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
World Lung 2025 – Bristol seeks PRMT5 biomarkers
A common mutation comes into play for PRMT5 inhibition.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
